Michael R. Hayden - Sep 13, 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Director
Signature: /s/ Tryn Stimart, attorney-in-fact
Stock symbol: ABCL
Transactions as of: Sep 13, 2021
Transactions value $: $4,787,100
Form type: 4
Date filed: 9/15/2021, 04:12 PM
Previous filing: Jul 19, 2021
Next filing: Oct 19, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABCL	Common Shares	Options Exercise	$4.79M	+270K	+26.91%	$17.73	1.27M	Sep 13, 2021	See footnote	F1
holding	ABCL	Common Shares						118K	Sep 13, 2021	By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABCL	Share option (right to buy)	Options Exercise	$0	+270K		$0.00	270K	Sep 13, 2021	Common Shares	270K	$0.32	See footnote	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.
F2	Per share exercise price has been converted from CAD to USD based on the grant date exchange ratio of CAD $1.32:USD $1.00 for September 11, 2019 as set forth on Bloomberg.
F3	The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on September 11, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date.